Aquestive Therapeutics, Inc. (AQST)

Market Cap	49.28M
Revenue (ttm)	48.08M
Net Income (ttm)	-71.00M
Shares Out	53.42M
EPS (ttm)	-1.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	83,150
Open	0.91
Previous Close	0.91
Day's Range	0.91 - 0.943
52-Week Range	0.618 - 6.25
Beta	2.79
Analysts	Buy
Price Target	5.61 (+499.2%)
Earnings Date	Nov 1, 2022

About AQST

Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with che...

• Industry: Pharmaceuticals
• IPO Date: Jul 25, 2018
• Employees: 157
• Stock Exchange: NASDAQ
• Ticker Symbol: AQST

Financial Performance

In 2021, AQST's revenue was $50.83 million, an increase of 10.87% compared to the previous year's $45.85 million. Losses were -$70.54 million, 26.5% more than in 2020.

Analyst Forecast

According to 13 analysts, the average rating for AQST stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 499.17% from the latest price.

Price Target

$5.61

(499.17% upside)

Analyst Consensus: Buy